Superworth

Illumina price to free cash flow ILMN

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026
43.7×
10-year median
56.7×
Against its 10-year history
23rd
percentile: 0 is its lowest day, 100 its highest
10-year range
13.7× to 337×
Peer median
30.7×

Illumina's price to free cash flow is 43.7× as of Oct 23, 2026.

That is below its ten-year median of 56.7×, lower than on 77% of days in the last ten years.

Over that time it ranged from 13.7× in Sep 2025 to 337× in Mar 2023.

The median for 10 diagnostics and research stocks of a similar size is 30.7×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far43.7×18.3×45.1×
202520.6×13.7×39.6×
202439.2×39.2×132×
2023127×86.1×337×
2022119×107×189×
2021123×57.2×132×
202056.3×39.6×69.4×
201968.7×48.7×68.7×
201851.4×48.1×69.5×
201756.8×46.4×61.5×
201642.2×37.3×60.2×
201565.4×52.6×82.4×
201466.8×49.5×88.1×
201350.3×24.1×50.3×
201227.1×14.0×27.9×
201113.4×11.8×36.3×

Against its peers

Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.

CompanyPrice to free cash flow
ILMNIllumina43.7×
IDXXIDEXX Laboratories35.2×
WATWaters112×
IQVIQVIA21.1×
AAgilent Technologies38.5×
MTDMettler-Toledo International38.7×
DGXQuest Diagnostics19.8×
LHLabcorp23.1×
MEDPMedpace26.4×
RVTYRevvity31.7×
DHRDanaher29.6×
Peer median30.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Illumina

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.